Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 420Precursor Cell Lymphoblastic Leukemia-Lymphoma 126Neoplasms, Plasma Cell 74Recurrence 70Lymphoma 57Leukemia 54Neoplasms 46Immunoglobulin Light-chain Amyloidosis 38Burkitt Lymphoma 37Vomiting 36Lymphoma, Mantle-Cell 32Lymphoma, Large B-Cell, Diffuse 31Nausea 29Lymphoma, Non-Hodgkin 28Breast Neoplasms 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 21Hodgkin Disease 21Leukemia, Lymphocytic, Chronic, B-Cell 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasm Metastasis 17Prostatic Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Amyloidosis 16Leukemia, Myeloid, Acute 15Smoldering Multiple Myeloma 14Lymphoma, B-Cell, Marginal Zone 13Lung Neoplasms 11Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 10

Interventions

Cyclophosphamide 4Gemcitabine 3isatuximab 2entrectinib 2cobimetinib 2capmatinib 2atezolizumab 2anlotinib 2alectinib 2Vemurafenib 2Sunitinib 2Rituximab 2Lenalidomide 2Dexamethasone 2Cisplatin 2trametinib 1spartalizumab 1pomalidomide 1pertuzumab 1penpulimab 1pembrolizumab 1olaparib 1niraparib 1lutetium Lu 177 dotatate 1ibritumomab tiuxetan 1fludarabine 1dabrafenib 1copper dotatate CU-64 1Trastuzumab 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neoplasms by Histologic Type × Dexamethasone × Clear all
NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡